Vomiting in docetaxel chemotherapy: which to blame, dose or gene?

The adverse effects (AEs) of docetaxel are major limiting factors of its success in the battle against cancer. AEs can be hematological and non-hematological (nausea, vomiting, diarrhea, rash and mucositis). Eventually, the dose is often reduced or regimen is diverted. Single nucleotide polymorphism...

Full description

Bibliographic Details
Main Authors: Jabir, Rafid, Ho, Gwo Fuang, Anuar, Muhammad Azrif, Stanslas, Johnson
Format: Article
Published: Federation of American Societies for Experimental Biology 2014
Online Access:http://psasir.upm.edu.my/id/eprint/35998/
_version_ 1848848210423971840
author Jabir, Rafid
Ho, Gwo Fuang
Anuar, Muhammad Azrif
Stanslas, Johnson
author_facet Jabir, Rafid
Ho, Gwo Fuang
Anuar, Muhammad Azrif
Stanslas, Johnson
author_sort Jabir, Rafid
building UPM Institutional Repository
collection Online Access
description The adverse effects (AEs) of docetaxel are major limiting factors of its success in the battle against cancer. AEs can be hematological and non-hematological (nausea, vomiting, diarrhea, rash and mucositis). Eventually, the dose is often reduced or regimen is diverted. Single nucleotide polymorphisms (SNPs) of genes encoding for proteins involved in the transport of docetaxel (ABCB1 and SLCO1B3) could potentially cause accumulation of the drug and consequent AEs. Therefore, we investigated the association between the SNPs (ABCB1 3435CT and SLCO1B3 334TG) and docetaxel AEs in seventy five Malaysian breast cancer patients receiving docetaxel as a single agent chemotherapy at 90-100 mg/m2 and 75 mg/m2 in the adjuvant and metastatic settings, respectively. The SNPs were analyzed using PCR-RFLP technique followed by DNA sequencing of selected samples. The patients were Chinese 37 (49%), Malays 32 (43%) and Indians 6 (8%). We found no significant association between the doses given and development of vomiting. However, Indian patients having ABCB1 3435TT (mutant) had a significant association with the development of vomiting (p=0.03). The SNPs-AEs association is an essential step in the achievement of personalized docetaxel chemotherapy milestones.
first_indexed 2025-11-15T09:30:53Z
format Article
id upm-35998
institution Universiti Putra Malaysia
institution_category Local University
last_indexed 2025-11-15T09:30:53Z
publishDate 2014
publisher Federation of American Societies for Experimental Biology
recordtype eprints
repository_type Digital Repository
spelling upm-359982016-02-18T00:57:33Z http://psasir.upm.edu.my/id/eprint/35998/ Vomiting in docetaxel chemotherapy: which to blame, dose or gene? Jabir, Rafid Ho, Gwo Fuang Anuar, Muhammad Azrif Stanslas, Johnson The adverse effects (AEs) of docetaxel are major limiting factors of its success in the battle against cancer. AEs can be hematological and non-hematological (nausea, vomiting, diarrhea, rash and mucositis). Eventually, the dose is often reduced or regimen is diverted. Single nucleotide polymorphisms (SNPs) of genes encoding for proteins involved in the transport of docetaxel (ABCB1 and SLCO1B3) could potentially cause accumulation of the drug and consequent AEs. Therefore, we investigated the association between the SNPs (ABCB1 3435CT and SLCO1B3 334TG) and docetaxel AEs in seventy five Malaysian breast cancer patients receiving docetaxel as a single agent chemotherapy at 90-100 mg/m2 and 75 mg/m2 in the adjuvant and metastatic settings, respectively. The SNPs were analyzed using PCR-RFLP technique followed by DNA sequencing of selected samples. The patients were Chinese 37 (49%), Malays 32 (43%) and Indians 6 (8%). We found no significant association between the doses given and development of vomiting. However, Indian patients having ABCB1 3435TT (mutant) had a significant association with the development of vomiting (p=0.03). The SNPs-AEs association is an essential step in the achievement of personalized docetaxel chemotherapy milestones. Federation of American Societies for Experimental Biology 2014-04 Article PeerReviewed Jabir, Rafid and Ho, Gwo Fuang and Anuar, Muhammad Azrif and Stanslas, Johnson (2014) Vomiting in docetaxel chemotherapy: which to blame, dose or gene? Journal of the Federation of American Societies for Experimental Biology, 28 (1 suppl.655.4). ISSN 0892-6638; ESSN: 1530-6860 http://www.fasebj.org/content/28/1_Supplement/655.4
spellingShingle Jabir, Rafid
Ho, Gwo Fuang
Anuar, Muhammad Azrif
Stanslas, Johnson
Vomiting in docetaxel chemotherapy: which to blame, dose or gene?
title Vomiting in docetaxel chemotherapy: which to blame, dose or gene?
title_full Vomiting in docetaxel chemotherapy: which to blame, dose or gene?
title_fullStr Vomiting in docetaxel chemotherapy: which to blame, dose or gene?
title_full_unstemmed Vomiting in docetaxel chemotherapy: which to blame, dose or gene?
title_short Vomiting in docetaxel chemotherapy: which to blame, dose or gene?
title_sort vomiting in docetaxel chemotherapy: which to blame, dose or gene?
url http://psasir.upm.edu.my/id/eprint/35998/
http://psasir.upm.edu.my/id/eprint/35998/